Stock NBIO NASCENT BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:55:21 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.0948 USD +5.33% Intraday chart for Nascent Biotech, Inc. -5.01% -45.17%
Apr. 16 Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run CI
Mar. 19 Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 6.882 5.387 11.98 6.334 6.308 7.162
Enterprise Value (EV) 1 6.765 5.255 12.11 6.494 6.214 7.38
P/E ratio -2.78 x -3.63 x -2.3 x -4.68 x -13.1 x -2.38 x
Yield - - - - - -
Capitalization / Revenue - - - 8,444,737 x 6,308,085 x -
EV / Revenue - - - 8,658,472 x 6,213,671 x -
EV / EBITDA - - - - - -
EV / FCF -5.82 x -26.5 x 11.2 x -2.44 x 15.6 x -3,398 x
FCF Yield -17.2% -3.78% 8.94% -41% 6.43% -0.03%
Price to Book -80.3 x -11.2 x -4.18 x -13.8 x -9.45 x -5.72 x
Nbr of stocks (in thousands) 27,527 32,647 44,690 102,154 110,668 127,331
Reference price 2 0.2500 0.1650 0.2680 0.0620 0.0570 0.0562
Announcement Date 6/29/18 7/12/19 6/22/20 7/8/21 6/15/22 6/29/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales - - - 0.75 1 -
EBITDA - - - - - -
EBIT 1 -2.222 -1.369 -3.447 -1.4 -0.4571 -2.14
Operating Margin - - - -186.72% -45.71% -
Earnings before Tax (EBT) 1 -2.221 -1.369 -4.004 -0.9588 -0.4704 -2.801
Net income 1 -2.221 -1.369 -4.004 -0.9588 -0.4704 -2.801
Net margin - - - -127.84% -47.04% -
EPS 2 -0.0900 -0.0455 -0.1164 -0.0133 -0.004365 -0.0236
Free Cash Flow 1 -1.162 -0.1985 1.083 -2.66 0.3995 -0.002172
FCF margin - - - -354.72% 39.95% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/29/18 7/12/19 6/22/20 7/8/21 6/15/22 6/29/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0.14 0.16 - 0.22
Net Cash position 1 0.12 0.13 - - 0.09 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.16 -0.2 1.08 -2.66 0.4 -0
ROE (net income / shareholders' equity) -686% 482% 238% 57.3% 82.2% 285%
ROA (Net income/ Total Assets) -273% -689% -3,199% -232% -66.7% -742%
Assets 1 0.8132 0.1988 0.1252 0.4133 0.7055 0.3773
Book Value Per Share 2 -0 -0.0100 -0.0600 -0 -0.0100 -0.0100
Cash Flow per Share 2 0 0 0 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 6/29/18 7/12/19 6/22/20 7/8/21 6/15/22 6/29/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NASCENT BIOTECH, INC. Stock Nascent Biotech, Inc.
-45.17% 16.17M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-1.05% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.87B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NBIO Stock
  4. Financials Nascent Biotech, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW